Compare CABA & SPCE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CABA | SPCE |
|---|---|---|
| Founded | 2017 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Transportation Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 227.2M | 207.3M |
| IPO Year | 2019 | N/A |
| Metric | CABA | SPCE |
|---|---|---|
| Price | $2.39 | $3.51 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 8 | 6 |
| Target Price | ★ $13.50 | $9.22 |
| AVG Volume (30 Days) | 2.2M | ★ 4.8M |
| Earning Date | 11-10-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,661,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $2,656.89 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.99 | $2.18 |
| 52 Week High | $3.67 | $6.77 |
| Indicator | CABA | SPCE |
|---|---|---|
| Relative Strength Index (RSI) | 48.61 | 47.33 |
| Support Level | $2.32 | $2.92 |
| Resistance Level | $2.48 | $4.57 |
| Average True Range (ATR) | 0.14 | 0.30 |
| MACD | -0.00 | -0.06 |
| Stochastic Oscillator | 17.50 | 35.15 |
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases.
Virgin Galactic Holdings Inc is a United States-based vertically integrated aerospace company pioneering human spaceflight for private individuals & researchers, and it also manufactures air and space vehicles. Using technologies, the company is developing a spaceflight system designed to offer its customers a multi-day, and transformative experience. This culminates in a spaceflight that includes views of Earth from space and several minutes of weightlessness that will launch from Spaceport America, New Mexico.